Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes

Biochemical Pharmacology

Volumn 56, Issue 2, 1998, Pages 243-251

  Yamazaki, Hiroshi ^a   Inoue, Kiyoshi ^a   Chiba, Koji ^b   Ozawa, Naoki ^b   Kawai, Takao ^a   Suzuki, Yasuhiko ^a   Goldstein, Joyce A ^c   Guengerich, F Peter ^d   Shimada, Tsutomu ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b Tsukuba Research Laboratories   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; Diclofenac; Flurbiprofen; Polymorphism; RT PCR; Warfarin

Indexed keywords

CYTOCHROME P450 ISOENZYME; DICLOFENAC; DRUG METABOLITE; FLURBIPROFEN; WARFARIN;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SUBSTITUTION; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DNA; FLURBIPROFEN; HETEROZYGOTE; HUMANS; HYDROXYLATION; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; RNA; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0031757521     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00133-6     Document Type: Article

References (40)

1. Gonzalez FJ, The molecular biology of cytochrome P450s. Pharmacol Rev 40: 243-288, 1989.
2. Guengerich FP, Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 266: 10019-10022, 1991.
3. Wilkinson GR, Guengerich FP and Branch RA, Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43: 53-76, 1989.
4. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994.
5. Goldstein JA and de Morais SMF, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-299, 1994.
6. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341-349, 1996.
7. Stubbins MJ, Harries LW, Smith G, Tarbit MH and Wolf CR, Genetic analysis of the human cytochrome P-450 CYP2C9 locus. Pharmacogenetics 6: 429-439, 1996.
8. Wang SL, Huang JD, Lai MD and Tsai JJ, Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5: 37-42, 1995.
9. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4†-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7: 103-113, 1997.
10. Bhasker CR, Miners JO, Coulter S and Birkett DJ, Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7: 51-58, 1997.
11. Yamazaki H, Inoue K, Turvy CG, Guengerich FP and Shimada T, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P-450 enzymes. Drug Metab Dispos 25: 168-174, 1997.
12. Guengerich FP, Analysis and characterization of enzymes. In: Principles and Methods of Toxicology (Ed. Hayes AW), pp. 1259-1313. Raven Press, New York, 1994.
13. Shimada T, Misono KS and Guengerich FP, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909-921, 1986.
14. Yasukochi Y and Masters BSS, Some properties of a detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J Biol Chem 251: 5337-5344, 1976.
15. Taniguchi H, Imai Y, Iyanagi T and Sato R, Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochim Biophys Acta 550: 341-356, 1979.
16. Kaminsky LS, Fasco MJ and Guengerich FP, Production and application of antibodies to rat liver cytochrome P-450. Methods Enzymol 74: 262-272, 1981.
17. Lang D and Böcker R, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxy-warfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672: 305-309, 1995.
18. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ and Korzekwa KR, Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49: 1269-1275, 1995.
19. TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 29-34, 1993.
20. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 325: 174-182, 1996.
21. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
22. Guengerich FP, Wang P and Davidson NK, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21: 1698-1706, 1982.
23. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
24. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ, Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1979.
25. Kawai T, Suzuki Y, Eda S, Ohtani K, Kase T, Fujinaga Y, Sakamoto T, Kurimura T and Wakamiya N, Cloning and characterization of a cDNA encoding bovine mannan-binding protein. Gene 186: 161-165, 1997.
26. Crespi CL and Miller VP, The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7: 203-210, 1997.
27. Haining RL, Hunter AP, Veronese ME, Trager WF and Rettie AE, Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333: 447-458, 1996.
28. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ and Korzekwa KR, Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52: 1305-1309, 1996.
29. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS and Guengerich FP, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993-4999, 1989.
30. Mancy A, Dijols S, Poli S, Guengerich FP and Mansuy D, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35: 16205-16212, 1996.
31. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF and Korzekwa KR, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4: 39-42, 1994.
32. Sandhu P, Baba T and Guengerich FP, Expression of modified human cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 306: 443-450, 1993.
33. Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP and Mansuy D, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur J Biochem 213: 223-232, 1993.
34. Yasumori T, Yamazoe Y and Kato R, Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: Differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. J Biochem (Tokyo) 109: 711-717, 1991.
35. Kaminsky LS, de Morais SMF, Faletto MB, Dunbar DA and Goldstein JA, Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 43: 234-239, 1993.
36. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA and Birkett DJ, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289: 533-538, 1993.
37. Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ and Idle JR, Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5: 389-392, 1995.
38. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, Lo M-W and Goldberg M, A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 59: 215, 1996.
39. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M and Wrighton SA, Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 22: 975-978, 1994.
40. Yamazaki H and Shimada T, Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 54: 1196-1203, 1997.